SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is experiencing mixed sentiment as the crypto market faces a pullback, with community members debating potential catalysts and expressing frustration over price stagnation. Some traders point to technical indicators suggesting a breakout is imminent, while others cite concerns about market manipulation. Ongoing discussions involve potential impacts from upcoming upgrades and institutional accumulation.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community debates recent price action and potential market manipulation, with some expressing frustration over its inability to maintain gains despite positive news. Discussions include trading strategies around swing trading and accumulating for long-term holds, while others point to upcoming events and ETFs as potential catalysts. Sentiment is mixed, with some users remaining bullish and others expressing skepticism about its future performance.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending amidst speculation of a potential partnership or acquisition, with names like TikTok and OpenAI being floated by the community. Some believe that a deal or buyout would be a major catalyst, especially with SNAP's advancements in AR glasses. The stock is also seeing increased volume and bullish options activity, fueling short squeeze hopes.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is surging, driven by speculative fervor around nuclear energy and AI data center applications, though the company is pre-revenue. Community chatter highlights both excitement and concern, with some traders pointing to a potential short squeeze while others warn of an unsustainable bubble. The stock's parabolic rise has drawn comparisons to past market frenzies, sparking debate about its long-term value in the context of the broader nuclear sector.

BlackBerry Ltd

BlackBerry is trending as investors discuss the potential impact of upcoming earnings and partnerships, particularly the integration of QNX with NVIDIA's Drive Thor. Community members are focused on revenue growth expectations, backlog conversion, and the potential for a QNX spin-off. Discussions also highlight BlackBerry's role in automotive cybersecurity and the Internet of Things.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as traders discuss a potential short squeeze, drawing comparisons to other AI defense stocks. The community is focused on key resistance levels, anticipating a continued rally and eyeing a move towards higher price targets. Some traders speculate on upcoming news or contract announcements as potential catalysts for further growth.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as community members highlight its strong, active, and creative community. Discussions revolve around the project's real-world presence through various businesses and products and organic growth. Community members express conviction in the project's long-term potential and encourage others to join.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending as the new iPhone 17 hits stores, with reports of strong demand and long lines, although some users are reporting scratching issues. Analysts are boosting price targets, citing a potential "supercycle" and AI capabilities in new devices, while the community debates the stock's valuation and potential for further gains. The stock's performance is also impacting broader market indexes like the QQQ and SPY.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending with community members noting its substantial trading volume and recent all-time highs, leading to discussions about its potential within the DeFi space. Bullish sentiment prevails, with many suggesting a long-term hold strategy amid comparisons to other exchanges and anticipation of further price appreciation. Some traders are also weighing the possibility of a pullback after this significant run.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending as investors discuss recent EU approval for Rybelsus and anticipation for FDA approval of its oral weight loss pill, Wegovy. Community members are actively adding shares, while also debating its competitive positioning against Eli Lilly ($LLY) in the GLP-1 market. Broader discussions involve the potential for next-generation treatments and expanding production capacity.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Boost Your Portfolio With These Top-Ranked ETFs

With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.

Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?

Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.

Top Wide-Moat Stocks Worth a Look for Sustainable Growth 

MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.

Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts

Johnson & Johnson (JNJ) reached $174.16 at the closing of the latest trading day, reflecting a -1.72% change compared to its last close.

J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why

J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.

Johnson &amp; Johnson (JNJ) said on Wednesday that its drug Icotrokinra showed superiority to Bristol Myers Squibb’s Deucravacitinib in head-to-head trials in the treatment of moderate-to-severe plaque psoriasis.Plaque psoriasis is a chronic immune-mediated disease characterized by the overproduction of skin cells, resulting in inflamed, scaly plaques that may be itchy or painful. According to Johnson &amp; Johnson, an estimated eight million Americans live with the disease.Icotrokinra demonstrated superior skin clearance at weeks 16 and 24 compared to Deucravacitinib in a late-stage study, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.jnj.com/media-center/press-releases/icotrokinra-shows-superiority-to-deucravacitinib-in-first-reported-head-to-head-trials-reinforcing-promise-of-novel-targeted-oral-peptide-for-treatment-of-plaque-psoriasis">stated</a>. Icotrokinra also showed sustained skin clearance and a favorable safety profile in both adults and adolescents at week 52 in the study, it added.The drug demonstrated similar adverse event rates (AEs) to those of the placebo, and Icotrokinra's adverse event rates were numerically lower compared to Deucravacitinib through week 24, the company stated. Deucravacitinib is marketed as Sotyktu by Bristol Myers.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/JNJ">JNJ stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_17_at_12_08_46_PM_png_6aafb85337.webp" alt="JNJ's Sentiment Meter and Message Volume as of 12:09 p.m. ET on Sept. 17, 2025 | Source: Stocktwits" width="575" height="63"><figcaption>JNJ's Sentiment Meter and Message Volume as of 12:09 p.m. ET on Sept. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted that the stock has been holding the $174-$180 range.<stembedurl>https://stocktwits.com/usiv/message/628943419</stembedurl>“These head-to-head data clearly demonstrate superior complete skin clearance rates for icotrokinra compared to deucravacitinib,” said Linda Stein Gold, a study investigator. “With significantly higher response rates seen as early as Week 16 and increasing at Week 24, this novel targeted oral peptide treatment has the potential to be an appealing new option for patients with moderate-to-severe plaque psoriasis.”Johnson &amp; Johnson also announced that it has initiated a new late-stage study, aiming to demonstrate the superiority of Icotrokinra compared to the company’s injectable biologic, Ustekinumab, in the treatment of psoriasis.Icotrokinra is the result of a license and collaboration agreement established between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson &amp; Johnson company, in 2017.Separately, JPMorgan raised its price target on Johnson &amp; Johnson to $195 from $185 on Tuesday, while maintaining a ‘Neutral’ rating on the shares.JNJ stock is up by 22% this year and by about 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-its-obesity-pill-topped-novo-nordisks-oral-drug-in-late-stage-diabetes-trial/chDGpSDRd6X">Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Study 

Icotrokinra demonstrated superior skin clearance at weeks 16 and 24 compared to Deucravacitinib in a late-stage study, the company said.

Equity

GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years

GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.

GSK’s U.S.-listed shares ticked&nbsp;nearly 2% higher after-hours Tuesday after the British drugmaker said it will pour $30 billion into U.S. research and manufacturing over the next five years,&nbsp;the latest move by a major pharmaceutical company to expand domestic production under President Donald Trump’s "America first" push.The investment includes a fresh $1.2 billion package to build new labs and factories, expand drug-substance production, and roll out AI and digital technology across five existing plants. GSK said the money will support hundreds of new high-skilled jobs alongside construction work.A centerpiece of the plan is a new biologics “flex” factory at Upper Merion, Pennsylvania, scheduled to break ground in 2026. The site will focus on medicines for respiratory illnesses such as asthma and COPD, as well as cancer. GSK is also adding new auto-injector and assembly capabilities as part of the push.“This week’s State Visit brings together two countries that have led the world in science and healthcare innovation,” CEO Emma Walmsley said, adding that the company’s $30 billion commitment would further cement its U.S. research and supply-chain base.The move comes as other global drugmakers step up U.S. spending. Earlier Tuesday, Eli Lilly announced a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-set-up-5-billion-facility-in-virginia/chwymFcRdzj">$5 billion facility west of Richmond, Virginia,</a> that will make complex cancer and autoimmune medicines and create more than 2,400 jobs. Johnson &amp; Johnson and AstraZeneca have each pledged around $50 billion in U.S. expansion by 2030.Big Pharma’s building spree&nbsp;indicates both opportunity and pressure&nbsp;as&nbsp;several companies are still trying to patch supply-chain weaknesses exposed during the Covid-19 pandemic, while the Trump administration has threatened tariffs of up to 250% on imported medicines.&nbsp;GSK, which employs about 15,000 people in the U.S., has already broken ground on an $800 million facility in Marietta, Pennsylvania, that will double that site’s capacity. Last year, GSK got 1.7 billion packs of medicine and 400 million vaccine doses into the hands of patients. By 2030, it wants to reach 2.5 billion people worldwide.On Stocktwits, retail sentiment for GSK was ‘neutral’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/GSK">GSK’s U.S.-listed stock</a> has risen 22.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

Johnson &amp; Johnson and Roche are reportedly in discussions with Shanghai Henlius Biotech, a unit of Fosun Pharma, over the rights to a new cancer drug. The potential deal comes as Washington weighs whether to tighten the rules&nbsp;for Chinese-developed medicines.HLX43, the cancer drug at the center of the talks, is in mid-stage trials in China. Henlius could be looking at a massive payday worth hundreds of millions upfront and potentially more if the drug shows strong results, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-16/fosun-s-henlius-is-said-in-talks-with-j-j-roche-on-cancer-drug">reported</a>, citing people familiar with the matter.&nbsp;However, the talks are apparently still in motion and may fall through. While J&amp;J and Roche declined to comment, Henlius dismissed the report as inaccurate without giving details. Negotiators reportedly noted that Henlius may also seek a higher valuation as more trial data becomes available.Last week, The New York Times&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2025/09/10/business/trump-medicines-china-biotech.html">reported</a> that the Trump administration is drafting an executive order that could put Chinese drug deals under stricter review by the Committee on Foreign Investment in the U.S. The draft would also increase scrutiny of Chinese clinical trial data and raise fees for Chinese-origin medicines.Western drugmakers have increasingly turned to China for new treatments. Pfizer and AstraZeneca are among those who have signed licensing deals to secure lower-cost experimental drugs. Analysts at Stifel estimate that by 2024, nearly a third of AbbVie’s and Merck’s external drug licenses came from Chinese biotechs, compared with about 10% just a few years earlier, according to a Seeking Alpha&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/news/4396390-chinese-biotech-dominance-rise#hasComeFromMpArticle=false">report</a>.&nbsp;On Stocktwits, retail sentiment for Johnson &amp; Johnson was ‘bearish’ on ‘normal’ message volume, while sentiment for Roche was ‘neutral’ with ‘low’ activity.While&nbsp;<a href="https://stocktwits.com/symbol/JNJ">Johnson &amp; Johnson’s stock</a> has risen 25.6% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/RHHBY">Roche’s U.S.-listed stock</a> has gained 20% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

While Johnson & Johnson’s stock (JNJ) has risen 25.6% so far in 2025, Roche’s U.S.-listed stock (RHHBY) has gained 20% over the same period. (Photo credit: Getty Images)

Big Pharma Eyes China: J&J And Roche Reportedly In Talks For Henlius’ Experimental Cancer Drug

The reported discussions highlight how Western drugmakers are increasingly turning to Chinese biotechs for promising treatments even as U.S. regulators weigh tougher scrutiny on such deals.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

JNJ
Johnson & Johnson

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest JNJ News

JNJ Johnson & Johnson